Komagata H, Yoneda S, Sakai H, Isobe K, Shirai T, Fujimura M, Tabei T, Inoue K
Department of Respiratory Disease, Saitama Cancer Center, Japan.
Int J Clin Pharmacol Res. 2005;25(4):195-202.
Patients receiving paclitaxel or docetaxel also receive a significant amount of ethanol, as both products contain ethanol as solvent. Patients in our clinics have occasionally exhibited signs of alcohol intoxication immediately after paclitaxel infusion. In 2002, the Japanese government lowered the minimum ethanol concentration for the definition of drunk driving, with the threshold breath alcohol concentration (BRAC) of 0.15 mg/l. The aim of this study was to measure BRAC in Japanese outpatients treated with paclitaxel or docetaxel and to assess intoxication according to this standard. Fifty-two Japanese patients were enrolled from October 2003 to February 2004. Patient characteristics were as follows: male/female, 13/39: median age, 71 (range: 34-78); breast/lung/ovarian cancer 24/16/12; and paclitaxel/docetaxel treatment: 36/16, respectively. The mean total doses of paclitaxel or docetaxel were 178 mg (range: 107-300) and 53 mg (30-100), respectively. Breath samples were measured three times immediately following the infusion of paclitaxel or docetaxel via ethyl alcohol detector and the mean value was recorded. BRAC was detected in 20 patients (56%) with paclitaxel and in none of the docetaxel patients. BRAC was measured again 30 min after the initial measurement in BRAC-detected cases with the patients' permission. In four of six BRAC-remeasured patients, BRAC became undetectable after 30 min. There was no correlation between the total doses of paclitaxel and BRAC or between the infusion rates of paclitaxel and BRAC. In conclusion, clinicians should recognize the potential for alcohol intoxication with paclitaxel administration. Patients should be instructed to avoid driving on the day of paclitaxel administration.
接受紫杉醇或多西他赛治疗的患者也会摄入大量乙醇,因为这两种产品都含有乙醇作为溶剂。我们诊所的患者在输注紫杉醇后偶尔会立即出现酒精中毒的迹象。2002年,日本政府降低了酒后驾车定义中的最低乙醇浓度,呼气酒精浓度(BRAC)阈值为0.15毫克/升。本研究的目的是测量接受紫杉醇或多西他赛治疗的日本门诊患者的BRAC,并根据该标准评估中毒情况。2003年10月至2004年2月招募了52名日本患者。患者特征如下:男/女,13/39;中位年龄,71岁(范围:34 - 78岁);乳腺癌/肺癌/卵巢癌患者分别为24/16/12例;接受紫杉醇/多西他赛治疗的患者分别为36/16例。紫杉醇或多西他赛的平均总剂量分别为178毫克(范围:107 - 300毫克)和53毫克(30 - 100毫克)。通过乙醇检测仪在输注紫杉醇或多西他赛后立即对呼气样本进行三次测量,并记录平均值。20例(56%)接受紫杉醇治疗的患者检测到BRAC,而接受多西他赛治疗的患者均未检测到。在检测到BRAC的病例中,经患者同意后于首次测量30分钟后再次测量BRAC。在六名再次测量BRAC的患者中,有四名患者在30分钟后BRAC检测不到。紫杉醇的总剂量与BRAC之间或紫杉醇的输注速率与BRAC之间均无相关性。总之,临床医生应认识到紫杉醇给药可能导致酒精中毒。应指导患者在紫杉醇给药当天避免驾驶。